LACTOLOGY FOUNDATION

Serotonin (5HT3) antagonists (ATC A04AA) are selective antiemetic agents used mainly for prevention and treatment of nausea and vomiting in oncology, radiotherapy and perioperative settings, with generally favorable safety in lactation when clinically indicated and used short term.medpedia.framar+4

Pharmacological class overview

Serotonin (5HT3) antagonists (also known as “setrons”) comprise ondansetron, granisetron, tropisetron, dolasetron and palonosetron, grouped under ATC code A04AA.atcddd.fhi+3
They act as selective competitive antagonists at peripheral and central 5HT3 receptors, blocking serotonin-induced activation of vagal afferents from the gastrointestinal tract and chemoreceptor trigger zone, thereby suppressing the vomiting reflex.drugbank+3

These agents are indicated for prevention and treatment of chemotherapy‑induced and radiotherapy‑induced nausea and vomiting, and for prevention and treatment of postoperative nausea and vomiting.ncbi.nlm.nih+4
They are commonly administered intravenously, as oral tablets, orally disintegrating tablets, or transdermal patches, depending on the specific compound and clinical context.hillman.upmc+3

Toxicological profile

In therapeutic doses, 5HT3 antagonists are generally well tolerated; the most frequent adverse reactions include headache, constipation, diarrhea and dizziness.accessdata.fda+3
Cardiac toxicity is primarily related to dose‑dependent QT interval prolongation and rare arrhythmias; this risk is better documented for ondansetron and granisetron and is greater with rapid high‑dose intravenous administration or in patients with pre‑existing risk factors.medsafe+2

Serious hypersensitivity reactions, including anaphylaxis, are rare but have been reported for the class.ncbi.nlm.nih+3
In overdose scenarios, expected toxic effects are extension of known adverse reactions (severe headache, marked constipation, hypotension, arrhythmias), and management is supportive, with cardiac monitoring and correction of electrolyte disturbances.accessdata.fda+2

From a reproductive toxicology standpoint, data in pregnancy and lactation are relatively limited for most compounds, hence product information often recommends cautious use, balancing maternal benefit against potential fetal or neonatal risk.healthinfo.healthengine+3
Nevertheless, extensive clinical use, especially of ondansetron in obstetric anaesthesia and postoperative care, has not revealed specific teratogenic or developmental toxicity signals in humans when used as indicated.mothertobaby+2

Lactological considerations

Transfer of 5HT3 antagonists into breast milk has been investigated best for ondansetron; pharmacokinetic studies show low milk‑to‑plasma ratios (approximately 0.15–0.37) and estimated infant doses below 1% of the maternal weight‑adjusted dose, which is far under the usual 10% concern threshold.doctronic+1
Plasma levels in breastfed infants whose mothers received standard intravenous ondansetron postpartum are typically undetectable, and no adverse effects have been reported in these infants.ncbi.nlm.nih+2

Based on available data and clinical experience, major expert sources classify ondansetron as usually compatible with breastfeeding when used in standard doses and for short durations.doctronic+2
It has even been administered directly to infants as young as one month of age for antiemetic indications, further supporting its relative safety profile in the breastfeeding context.mothertobaby+1

For granisetron, dolasetron, tropisetron and palonosetron, human lactation data are sparse or absent; product labels generally state that excretion in human milk is unknown and recommend caution or restriction of use during lactation to situations where clear maternal benefit justifies potential risk.drugcentral+3
In practice, short‑term use of these agents in breastfeeding women is usually considered acceptable when strong antiemetic control is needed and safer alternatives are not suitable, but decisions should be individualized and accompanied by monitoring of the infant for sedation, feeding difficulties or gastrointestinal disturbances.breastfeeding+2

Clinical use in breastfeeding women

In breastfeeding women undergoing chemotherapy, radiotherapy or surgery, 5HT3 antagonists may be required to secure effective control of nausea and vomiting, which in turn supports adequate nutrition and maintenance of breastfeeding.hillman.upmc+3
Ondansetron is often preferred due to better lactation data, wide clinical experience and favorable pharmacokinetics, including low oral bioavailability in the infant via breast milk exposure and limited cumulative dosing when used around specific procedures.ncbi.nlm.nih+3

Key practical principles include using the lowest effective dose for the shortest duration, avoiding high‑dose or prolonged regimens when not strictly necessary, and timing breastfeeding (when feasible) shortly before maternal dosing to minimize peak milk concentrations.breastfeeding+2
Routine interruption of breastfeeding is generally unnecessary for short‑term standard‑dose ondansetron, whereas for less‑studied setrons, temporary monitoring and shared decision‑making with the mother regarding feeding patterns may be appropriate.healthinfo.healthengine+3

For neonates and premature infants, theoretical susceptibility to QT prolongation and serotonergic modulation warrants additional caution; clinicians should consider baseline risk factors and observe for changes in feeding behavior, alertness or gastrointestinal function.medsafe+3
When multiple QT‑prolonging drugs are prescribed to the mother (for example, certain antidepressants or antiarrhythmics), cardiotoxic risk assessment should be revisited, although the absolute exposure of the breastfed infant to the setron remains small.ncbi.nlm.nih+2

Summary table: ATC A04AA in lactation